Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by pericles1on Feb 19, 2011 9:51am

364 Views

Post# 18163411

RE: Upgraded UK H&N results

Rjc, I agree that having one turn to a complete response is positive, sorry to see the other two die. The problem is that one is always seen as an aberation by experts. Two would have been great. i can remember a small early trial in Thyroid cancer by Oxegene a company I owned at one time, they had a complete response and cure actually because he was still alive years later. Only 14 patients if I remember right and they could not duplicate in a larger trial later which was a big diappointment!

I'm still very confident but trials are tricky!

Bullboard Posts

Gold vs. bitcoin, where should you invest?